Between the ongoing, and dragged out Brexit shifts, and improving bioscience (immuno-oncology) pipeline deliveries, Merck's MSD subsidiaries are now expanding in and near London, as well as in Dublin -- one of my favorite places on the green Earth. Smile. Here's the bit, from Irish Times:
. . . .MSD’s US parent, the drug giant Merck, is looking to ramp up global manufacturing capacity for its blockbuster cancer therapy Keytruda. At present the group has only one immuno-oncology manufacturing base, with the rest of its supplies delivered by contract manufacturing partners.
Ger Brennan, managing director of MSD Human Health, said the company expected “significant growth” in immuno-oncology over the coming years.
“We need to have confidence in supply,” he said.
MSD expects the new facility to be operational in 2021 and fully certified by 2022. “It’s a bold statement by MSD,” said Mr Brennan, “but that’s our target.”
The Swords investment will be a “significant component” of the €4 billion capital expenditure plan outlined by the US group earlier this month, Mr Brennan said, although MSD did not disclose the amount of its investment. . . .
Now you know -- smiling, as quite leprechaun-like. . . I vanish.
नमस्ते
No comments:
Post a Comment